Clinical Trial Update: Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 safety study of BAY73-4506 in patients with hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• BAY73-4506 (BAY-73-4506)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: COMPLETED